Treatment Patterns & Clinical Outcomes of Palbociclib Combinations in HR+HER2-MBC

About the study

The objective of this non-interventional multicenter study is to provide prospective, observational data on patients initiating treatment with palbociclib combination to contribute to the knowledge of HR+ HER2-metastatic/locally advanced Breast Cancer (BC) disease management, its treatment pattern, clinical outcomes and quality of life (QoL) in the routine clinical practice in Africa and Middle East countries .

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

≥18 years or older with diagnosis of adenocarcinoma of the breast with evidence of metastatic /locally advanced disease not amenable to treatment with curative intent.
Documented HR+ (ER+ and/or PR+) tumor based on local standards
Documented HER2- tumor based on local standards
Will initiate treatment with palbociclib plus letrozole/aromatase inhibitor or palbociclib plus fulvestrant in line with the licensed indication(s), as first or second line therapy for metastatic/locally advanced BC at enrollment
Patients who in the opinion of the investigator are willing and able to comply with regular clinic visits
Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

EXCLUSION CRITERIA

Exclusion Criteria:

Patients participating in any interventional clinical trial
Patients on active treatment for malignancies other than metastatic/locally advanced BC at the time of enrollment
Patients who are unable to understand the nature of the study and are unwilling to sign an informed consent